Clinical trials: Overweight and/or Obesity
Obesity, Overweight
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric…
- Trial name
- ADVANCE (NCT06672549)
- Testing
- Orforglipron
- Where
- 116 sites in United States, Belgium and 11 more
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Obesity & Overweight
A Study of SGB-7342 in Subjects With Obesity or Overweight
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
- Trial name
- NCT07324850
- Testing
- SGB-7342
- Volunteers
- 45 people
- Sponsor
- Suzhou Sanegene Bio Inc.
Obesity, Overweight
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight.
- Trial name
- NCT07684235
- Testing
- Maridebart cafraglutide
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 3,200 people
- Sponsor
- Amgen
Overweight, Obesity
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity.
- Trial name
- NCT06916065
- Testing
- Eloralintide and Tirzepatide, Eloralintide
- Where
- 3 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eli Lilly and Company
Overweight , Obesity
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07791654
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Diabetes Mellitus, Type 2, Obesity
A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight
Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and excess body weight.
- Trial name
- NCT07004322
- Testing
- NNC0519-0130
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Healthy Subjects
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose…
- Trial name
- NCT07102251
- Testing
- HEC-007 injection
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Overweight and Obesity
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
- Trial name
- NCT07313761
- Testing
- Maridebart Cafraglutide
- Where
- 4 sites in United States
- Volunteers
- 349 people
- Sponsor
- Amgen
Overweight, Obesity
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.
- Trial name
- NCT06904105
- Testing
- HRS-7535 Tablets
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066
The purpose of this study was to determine if LIK066 taken with a meal containing low carbohydrate is associated with less diarrhea compared to a high carbohydrate meal and to assess the potential effects of supplements such as…
- Trial name
- NCT03198767
- Testing
- LIK066, Carbohydrate 50%, Carbohydrate 25%
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Overweight
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes.
- Conditions
- Diabetes Mellitus, Overweight, Obesity
- Trial name
- AMAZE 2 (NCT07533175)
- Testing
- NNC0487-0111
- Where
- 74 sites in United States, Argentina and 8 more
- Volunteers
- 630 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
- Trial name
- NCT00402077
- Testing
- pramlintide acetate, sibutramine, phentermine
- Where
- 16 sites in United States
- Volunteers
- 258 people
- Sponsor
- AstraZeneca
Obesity
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
- Trial name
- NCT06277934
- Testing
- RGT001-075
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Regor Pharmaceuticals Inc.
Overweight, Obesity
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity.
- Trial name
- NCT07557953
- Testing
- Cagrilintide
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Obesity, Non-Alcoholic SteatoHepatitis (NASH)
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
This study is open to adults who are at least 18 years old and have presumed or confirmed NASH together with overweight or obesity and a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² and at least one…
- Trial name
- NCT06309992
- Testing
- Survodutide
- Where
- 37 sites in United States, Spain
- Volunteers
- 218 people
- Sponsor
- Boehringer Ingelheim
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
- Trial name
- ATTAIN-CN (NCT07790861)
- Testing
- Orforglipron
- Where
- 13 sites in China
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Obesity
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide.
- Trial name
- NCT06716307
- Testing
- CagriSema (cagrilintide B and semaglutide I), CagriSema A
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07868354
- Testing
- Tirzepatide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company